Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of... Am J Cardiovasc Drugs (2018) 18:109–115 https://doi.org/10.1007/s40256-017-0250-3 ORIGINAL RESEARCH ARTICLE Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease 1 2 3 3 • • • • Stephen J. Nicholls Kausik K. Ray Jan O. Johansson Alan Gordon 3 3 3 3 • • • • Michael Sweeney Chris Halliday Ewelina Kulikowski Norman Wong 1 4 Susan W. Kim Gregory G. Schwartz Published online: 12 October 2017 Springer International Publishing AG 2017 Abstract dyslipidemia, and be undertreated with ß-blocker and anti- Background Inhibition of bromodomain and extra-terminal platelet agents. Treatment with apabetalone produced the (BET) proteins can modulate lipoprotein and inflammatory following dose-dependent changes compared with placebo: factors that mediate atherosclerosis. The impact of the BET increases in apolipoprotein A-I (apoA-I) of up to 6.7% inhibitor, apabetalone, on cardiovascular events is unknown. (P \ 0.001), increases in high-density lipoprotein choles- Objective Our objective was to investigate the impact of terol (HDL-C) of up to 6.5% (P \ 0.001), increases in apabetalone on cardiovascular event rates in a pooled large HDL particles of up to 23.3% (P\ 0.001), and analysis of clinical studies in patients with established decreases in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

Loading next page...
 
/lp/springer_journal/selective-bet-protein-inhibition-with-apabetalone-and-cardiovascular-tsLvlIhsDs
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
D.O.I.
10.1007/s40256-017-0250-3
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2018) 18:109–115 https://doi.org/10.1007/s40256-017-0250-3 ORIGINAL RESEARCH ARTICLE Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease 1 2 3 3 • • • • Stephen J. Nicholls Kausik K. Ray Jan O. Johansson Alan Gordon 3 3 3 3 • • • • Michael Sweeney Chris Halliday Ewelina Kulikowski Norman Wong 1 4 Susan W. Kim Gregory G. Schwartz Published online: 12 October 2017 Springer International Publishing AG 2017 Abstract dyslipidemia, and be undertreated with ß-blocker and anti- Background Inhibition of bromodomain and extra-terminal platelet agents. Treatment with apabetalone produced the (BET) proteins can modulate lipoprotein and inflammatory following dose-dependent changes compared with placebo: factors that mediate atherosclerosis. The impact of the BET increases in apolipoprotein A-I (apoA-I) of up to 6.7% inhibitor, apabetalone, on cardiovascular events is unknown. (P \ 0.001), increases in high-density lipoprotein choles- Objective Our objective was to investigate the impact of terol (HDL-C) of up to 6.5% (P \ 0.001), increases in apabetalone on cardiovascular event rates in a pooled large HDL particles of up to 23.3% (P\ 0.001), and analysis of clinical studies in patients with established decreases in

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Oct 12, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off